Drug
5-ALA
5-ALA is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_1
2
40%
Ph early_phase_1
1
20%
Ph not_applicable
1
20%
Ph phase_2
1
20%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(1)
Other(3)
Detailed Status
unknown2
Suspended1
Not yet recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (20.0%)
Phase 12 (40.0%)
Phase 21 (20.0%)
N/A1 (20.0%)
Trials by Status
unknown240%
suspended120%
not_yet_recruiting120%
completed120%
Recent Activity
0 active trials
Showing 5 of 5
not_yet_recruitingearly_phase_1
5-AminoLevulinic Acid Aided Resection Margins in Sarcoma
NCT07038278
suspendedphase_1
Phase I Study in Advanced Malignancies With 5-ALA
NCT04381806
completedphase_2
Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
NCT01310868
unknownnot_applicable
5-ALA in Recurrent Glioma
NCT02119338
unknownphase_1
The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors
NCT02050243
Clinical Trials (5)
Showing 5 of 5 trials
NCT07038278Early Phase 1
5-AminoLevulinic Acid Aided Resection Margins in Sarcoma
NCT04381806Phase 1
Phase I Study in Advanced Malignancies With 5-ALA
NCT01310868Phase 2
Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
NCT02119338Not Applicable
5-ALA in Recurrent Glioma
NCT02050243Phase 1
The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5